Lipocine Inc.
NASDAQ:LPCN
Overview | Financials
Company Name | Lipocine Inc. |
Symbol | LPCN |
Currency | USD |
Price | 4.43 |
Market Cap | 23,691,374 |
Dividend Yield | 0% |
52-week-range | 3.2 - 11.79 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mahesh V. Patel Ph.D. |
Website | https://www.lipocine.com |
An error occurred while fetching data.
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD